Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year
- Posted on July 23, 2026
- By International Business Times
- 0 Views
- 1 min read
In brief
Generating AI summary…
Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year
After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.
